327 related articles for article (PubMed ID: 16787142)
1. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
[TBL] [Abstract][Full Text] [Related]
2. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
Dimopoulos MA; Kiamouris C; Gika D; Deliveliotis C; Giannopoulos A; Zervas A; Alamanis C; Constantinidis C; Koutsilieris M
Urology; 2004 Jan; 63(1):120-5. PubMed ID: 14751362
[TBL] [Abstract][Full Text] [Related]
3. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
[TBL] [Abstract][Full Text] [Related]
4. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
5. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.
Koutsilieris M; Mitsiades C; Dimopoulos T; Vacalicos J; Lambou T; Tsintavis A; Milathianakis C; Bogdanos J; Karamanolakis D
Expert Opin Investig Drugs; 2002 Feb; 11(2):283-93. PubMed ID: 11829717
[TBL] [Abstract][Full Text] [Related]
6. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
7. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
Koutsilieris M; Dimopoulos T; Milathianakis C; Bogdanos J; Karamanolakis D; Pissimissis N; Halapas A; Lembessis P; Papaioannou A; Sourla A
BJU Int; 2007 Jul; 100 Suppl 2():60-2. PubMed ID: 17594363
[No Abstract] [Full Text] [Related]
8. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
Pienta KJ;
Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
[TBL] [Abstract][Full Text] [Related]
9. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report.
Koutsilieris M; Tzanela M; Dimopoulos T
Prostate; 1999 Mar; 38(4):313-6. PubMed ID: 10075011
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy of prostate cancer.
Bare RL; Torti FM
Cancer Treat Res; 1998; 94():69-87. PubMed ID: 9587683
[TBL] [Abstract][Full Text] [Related]
11. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
Cerulli C; Sciarra A; Salvatori G; Di Silverio F
Urology; 2004 Dec; 64(6):1231.e1-3. PubMed ID: 15596212
[TBL] [Abstract][Full Text] [Related]
12. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
13. Hormone therapy in advanced prostate cancer.
Forster TH; Stoffel F; Gasser TC
Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
[No Abstract] [Full Text] [Related]
14. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients.
Vaz S; Hadaschik B; Gabriel M; Herrmann K; Eiber M; Costa D
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):9-15. PubMed ID: 31654093
[No Abstract] [Full Text] [Related]
15. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
16. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
[TBL] [Abstract][Full Text] [Related]
17. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.
Bogdanos J; Karamanolakis D; Tenta R; Tsintavis A; Milathianakis C; Mitsiades C; Koutsilieris M
Endocr Relat Cancer; 2003 Jun; 10(2):279-89. PubMed ID: 12790789
[TBL] [Abstract][Full Text] [Related]
18. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Belanger A; Lachance R; Emond J; Monfette G
J Steroid Biochem; 1987; 27(1-3):525-32. PubMed ID: 2961937
[TBL] [Abstract][Full Text] [Related]
20. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
